A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Five Different Doses of Inhaled Indacaterol (QAB149) Delivered Via the Single Dose Dry Powder Inhaler (SDDPI) in Patients With Persistent Asthma

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Five Different Doses of Inhaled Indacaterol (QAB149) Delivered Via the Single Dose Dry Powder Inhaler (SDDPI) in Patients With Persistent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2015

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Indacaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 16 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top